FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997804547> ?p ?o ?g. }

• W1997804547 endingPage "813" @default.
• W1997804547 startingPage "795" @default.
• W1997804547 abstract "Haematopoietic stem cell-supported myeloablative therapy appears to be a promising treatment modality for MM. It yields increased overall response and CR rates when compared with conventional chemotherapy, and seems to prolong the duration of survival. These conclusions, while encouraging, have mostly been drawn from uncontrolled studies carried out in select groups of patients and, obviously, need to be confirmed in controlled clinical trials. While the results of these studies are still awaited, the wider application of BMT should probably be encouraged. As in other malignancies, the best candidates appear to be those less heavily pre-treated, with chemosensitive disease, low tumour cell mass and other favourable prognostic features, for example low beta 2-microglobulin levels. Under these conditions, the chance of entering CR following BMT, be it autologous or allogeneic, is currently estimated to be of at least 50%, and the long-term probability of survival averages approximately 30%. However, while it appears that a plateau for progression-free survival cannot be ascertained following a single ABMT, reported observations of patients with continued disease-free survivals up to and beyond 10 years after allografting suggest that this latter procedure may be curative. It seems likely therefore that the higher mortality related to allogeneic BMT (which in recent years decreased from 50% to approximately 30% as the results of a better selection of patients and increasing experience in their management) may be offset by more durable control of the disease and cure in a certain proportion of patients. Recurrence of underlying malignant disease remains, however, a major problem and is the most common cause of treatment failure following BMT. For this reason, attempts to improve the impact of transplantation are warranted. Options currently under investigation include the development of more effective conditioning regimens, as applied in double auto-transplant or with targeted therapy using antibody-radionuclide conjugates, as well as post-transplant immunomodulation with either IFN-alpha, interleukin-2 or idiotype vaccines. In addition, many other problems regarding BMT for MM are still unresolved and could be properly addressed only in future clinical trials. The most important of these issues include the choice of the best conditioning regimen and the optimal source of haematopoietic stem cells, the nature of relapse after autografting, the need to purge or not to purge the autologous marrow, the existence of a 'graft-versus-myeloma' effect and its role in prolonging the duration of disease control and, finally, the likelihood of cure, especially for patients with molecularly-defined CR." @default.
• W1997804547 created "2016-06-24" @default.
• W1997804547 creator A5031078901 @default.
• W1997804547 creator A5033359713 @default.
• W1997804547 creator A5067436666 @default.
• W1997804547 creator A5071926851 @default.
• W1997804547 date "1995-12-01" @default.
• W1997804547 modified "2023-09-25" @default.
• W1997804547 title "6The role of haematopoietic stem cell-supported myeloablative therapy for the management of multiple myeloma" @default.
• W1997804547 cites W123117430 @default.
• W1997804547 cites W1233091556 @default.
• W1997804547 cites W147513325 @default.
• W1997804547 cites W1498384332 @default.
• W1997804547 cites W1526986700 @default.
• W1997804547 cites W1581344599 @default.
• W1997804547 cites W1589566672 @default.
• W1997804547 cites W16036224 @default.
• W1997804547 cites W1840931904 @default.
• W1997804547 cites W1897829250 @default.
• W1997804547 cites W1914208484 @default.
• W1997804547 cites W1949358987 @default.
• W1997804547 cites W195783192 @default.
• W1997804547 cites W1964073968 @default.
• W1997804547 cites W1969349875 @default.
• W1997804547 cites W197334239 @default.
• W1997804547 cites W2000347044 @default.
• W1997804547 cites W2001659596 @default.
• W1997804547 cites W2006909493 @default.
• W1997804547 cites W2019442206 @default.
• W1997804547 cites W2026295989 @default.
• W1997804547 cites W2034699896 @default.
• W1997804547 cites W2051791220 @default.
• W1997804547 cites W2056165583 @default.
• W1997804547 cites W2083144698 @default.
• W1997804547 cites W2083517973 @default.
• W1997804547 cites W2089356133 @default.
• W1997804547 cites W2105631437 @default.
• W1997804547 cites W2128133990 @default.
• W1997804547 cites W2130358507 @default.
• W1997804547 cites W2142015222 @default.
• W1997804547 cites W2162992800 @default.
• W1997804547 cites W2208728563 @default.
• W1997804547 cites W2262776735 @default.
• W1997804547 cites W2271876496 @default.
• W1997804547 cites W2290337133 @default.
• W1997804547 cites W2301504565 @default.
• W1997804547 cites W2313423582 @default.
• W1997804547 cites W2403891544 @default.
• W1997804547 cites W2405211608 @default.
• W1997804547 cites W2406235341 @default.
• W1997804547 cites W2408862815 @default.
• W1997804547 cites W2411515339 @default.
• W1997804547 cites W2413404062 @default.
• W1997804547 cites W2413735978 @default.
• W1997804547 cites W2413907380 @default.
• W1997804547 cites W2414206598 @default.
• W1997804547 cites W2416000148 @default.
• W1997804547 cites W2416643931 @default.
• W1997804547 cites W2418260674 @default.
• W1997804547 cites W2418641834 @default.
• W1997804547 cites W2433538213 @default.
• W1997804547 cites W2466294727 @default.
• W1997804547 cites W35670799 @default.
• W1997804547 cites W38065407 @default.
• W1997804547 cites W98986799 @default.
• W1997804547 cites W2124601853 @default.
• W1997804547 doi "https://doi.org/10.1016/s0950-3536(05)80260-4" @default.
• W1997804547 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8845573" @default.
• W1997804547 hasPublicationYear "1995" @default.
• W1997804547 type Work @default.
• W1997804547 sameAs 1997804547 @default.
• W1997804547 citedByCount "11" @default.
• W1997804547 countsByYear W19978045472013 @default.
• W1997804547 crossrefType "journal-article" @default.
• W1997804547 hasAuthorship W1997804547A5031078901 @default.
• W1997804547 hasAuthorship W1997804547A5033359713 @default.
• W1997804547 hasAuthorship W1997804547A5067436666 @default.
• W1997804547 hasAuthorship W1997804547A5071926851 @default.
• W1997804547 hasConcept C109159458 @default.
• W1997804547 hasConcept C126322002 @default.
• W1997804547 hasConcept C141071460 @default.
• W1997804547 hasConcept C143998085 @default.
• W1997804547 hasConcept C2776364478 @default.
• W1997804547 hasConcept C2776694085 @default.
• W1997804547 hasConcept C2779134260 @default.
• W1997804547 hasConcept C28328180 @default.
• W1997804547 hasConcept C54355233 @default.
• W1997804547 hasConcept C71924100 @default.
• W1997804547 hasConcept C86803240 @default.
• W1997804547 hasConceptScore W1997804547C109159458 @default.
• W1997804547 hasConceptScore W1997804547C126322002 @default.
• W1997804547 hasConceptScore W1997804547C141071460 @default.
• W1997804547 hasConceptScore W1997804547C143998085 @default.
• W1997804547 hasConceptScore W1997804547C2776364478 @default.
• W1997804547 hasConceptScore W1997804547C2776694085 @default.
• W1997804547 hasConceptScore W1997804547C2779134260 @default.
• W1997804547 hasConceptScore W1997804547C28328180 @default.
• W1997804547 hasConceptScore W1997804547C54355233 @default.

• next